{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T18:47:06Z","timestamp":1784832426998,"version":"3.55.0"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,11,28]],"date-time":"2024-11-28T00:00:00Z","timestamp":1732752000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2024,11,28]],"date-time":"2024-11-28T00:00:00Z","timestamp":1732752000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-024-81028-3","type":"journal-article","created":{"date-parts":[[2024,11,28]],"date-time":"2024-11-28T14:37:09Z","timestamp":1732804629000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Prognostic significance of serum interleukin-6 in severe\/critical COVID-19 patients treated with tocilizumab: a detailed observational study analysis"],"prefix":"10.1038","volume":"14","author":[{"given":"Panpan","family":"Liang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li\u2019e","family":"Meng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuting","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hailing","family":"Mai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tao","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiarui","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junhui","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bing","family":"Zhuan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,11,28]]},"reference":[{"key":"81028_CR1","doi-asserted-by":"crossref","unstructured":"The Novel Coronavirus Pneumonia Emergency Response Epidemiology, T. The Epidemiological Characteristics of an Outbreak of 2019 Novel Coronavirus Diseases (COVID-19)-China, 2020. China CDC Wkly 2, 113\u2013122 (2020).","DOI":"10.46234\/ccdcw2020.032"},{"key":"81028_CR2","doi-asserted-by":"publisher","DOI":"10.15252\/emmm.202012421","volume":"12","author":"T Liu","year":"2020","unstructured":"Liu, T. et al. The role of interleukin-6 in monitoring severe case of coronavirus disease 2019. EMBO Mol. Med. 12, e12421. https:\/\/doi.org\/10.15252\/emmm.202012421 (2020).","journal-title":"EMBO Mol. Med."},{"key":"81028_CR3","doi-asserted-by":"publisher","first-page":"1054","DOI":"10.1016\/s0140-6736(20)30566-3","volume":"395","author":"F Zhou","year":"2020","unstructured":"Zhou, F. et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: A retrospective cohort study. Lancet 395, 1054\u20131062. https:\/\/doi.org\/10.1016\/s0140-6736(20)30566-3 (2020).","journal-title":"Lancet"},{"key":"81028_CR4","doi-asserted-by":"publisher","first-page":"1491","DOI":"10.1056\/NEJMoa2100433","volume":"384","author":"AC Gordon","year":"2021","unstructured":"Gordon, A. C. et al. Interleukin-6 receptor antagonists in critically ill patients with Covid-19. N. Engl. J. Med. 384, 1491\u20131502. https:\/\/doi.org\/10.1056\/NEJMoa2100433 (2021).","journal-title":"N. Engl. J. Med."},{"key":"81028_CR5","doi-asserted-by":"publisher","first-page":"2648","DOI":"10.1002\/jmv.26111","volume":"92","author":"B Borku Uysal","year":"2020","unstructured":"Borku Uysal, B. et al. Tocilizumab challenge: A series of cytokine storm therapy experiences in hospitalized COVID-19 pneumonia patients. J. Med. Virol. 92, 2648\u20132656. https:\/\/doi.org\/10.1002\/jmv.26111 (2020).","journal-title":"J. Med. Virol."},{"key":"81028_CR6","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/j.ejim.2020.05.009","volume":"76","author":"R Capra","year":"2020","unstructured":"Capra, R. et al. Impact of low dose tocilizumab on mortality rate in patients with COVID-19 related pneumonia. Eur. J. Intern. Med. 76, 31\u201335. https:\/\/doi.org\/10.1016\/j.ejim.2020.05.009 (2020).","journal-title":"Eur. J. Intern. Med."},{"key":"81028_CR7","doi-asserted-by":"publisher","unstructured":"Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): A randomised, controlled, open-label, platform trial. Lancet 397, 1637\u20131645, https:\/\/doi.org\/10.1016\/s0140-6736(21)00676-0 (2021).","DOI":"10.1016\/s0140-6736(21)00676-0"},{"key":"81028_CR8","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1001\/jama.2021.11330","volume":"326","author":"M Shankar-Hari","year":"2021","unstructured":"Shankar-Hari, M. et al. Association between administration of IL-6 antagonists and mortality among patients hospitalized for COVID-19: A meta-analysis. Jama 326, 499\u2013518. https:\/\/doi.org\/10.1001\/jama.2021.11330 (2021).","journal-title":"Jama"},{"key":"81028_CR9","doi-asserted-by":"publisher","first-page":"1027","DOI":"10.1111\/resp.14152","volume":"26","author":"C Kyriakopoulos","year":"2021","unstructured":"Kyriakopoulos, C. et al. Tocilizumab administration for the treatment of hospitalized patients with COVID-19: A systematic review and meta-analysis. Respirology 26, 1027\u20131040. https:\/\/doi.org\/10.1111\/resp.14152 (2021).","journal-title":"Respirology"},{"key":"81028_CR10","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaut.2020.102523","volume":"114","author":"O Moreno-P\u00e9rez","year":"2020","unstructured":"Moreno-P\u00e9rez, O. et al. Experience with tocilizumab in severe COVID-19 pneumonia after 80 days of follow-up: A retrospective cohort study. J. Autoimmun. 114, 102523. https:\/\/doi.org\/10.1016\/j.jaut.2020.102523 (2020).","journal-title":"J. Autoimmun."},{"key":"81028_CR11","doi-asserted-by":"publisher","unstructured":"RC N H C O T, MEDICINE N A O T C. Diagnosis and treatment plan for COVID.19(trial version 10). Inter. J. Epidemiol. Infect. Dis., 36(01): 18\u201325, https:\/\/doi.org\/10.3760\/j.issn.1673-4777.2023.02.001 (2023).","DOI":"10.3760\/j.issn.1673-4777.2023.02.001"},{"key":"81028_CR12","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1016\/s2213-2600(21)00103-x","volume":"9","author":"OJ McElvaney","year":"2021","unstructured":"McElvaney, O. J., Curley, G. F., Rose-John, S. & McElvaney, N. G. Interleukin-6: Obstacles to targeting a complex cytokine in critical illness. Lancet Respir. Med. 9, 643\u2013654. https:\/\/doi.org\/10.1016\/s2213-2600(21)00103-x (2021).","journal-title":"Lancet Respir. Med."},{"key":"81028_CR13","doi-asserted-by":"publisher","first-page":"1233","DOI":"10.1016\/s2213-2600(20)30404-5","volume":"8","author":"DE Leisman","year":"2020","unstructured":"Leisman, D. E. et al. Cytokine elevation in severe and critical COVID-19: A rapid systematic review, meta-analysis, and comparison with other inflammatory syndromes. Lancet Respir. Med. 8, 1233\u20131244. https:\/\/doi.org\/10.1016\/s2213-2600(20)30404-5 (2020).","journal-title":"Lancet Respir. Med."},{"key":"81028_CR14","doi-asserted-by":"publisher","first-page":"3959","DOI":"10.1182\/blood-2008-05-155846","volume":"112","author":"N Nishimoto","year":"2008","unstructured":"Nishimoto, N. et al. Mechanisms and pathologic significances in increase in serum interleukin-6 (IL-6) and soluble IL-6 receptor after administration of an anti-IL-6 receptor antibody, tocilizumab, in patients with rheumatoid arthritis and Castleman disease. Blood 112, 3959\u20133964. https:\/\/doi.org\/10.1182\/blood-2008-05-155846 (2008).","journal-title":"Blood"},{"key":"81028_CR15","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1111\/joim.13162","volume":"289","author":"J Eimer","year":"2021","unstructured":"Eimer, J. et al. Tocilizumab shortens time on mechanical ventilation and length of hospital stay in patients with severe COVID-19: A retrospective cohort study. J. Intern. Med. 289, 434\u2013436. https:\/\/doi.org\/10.1111\/joim.13162 (2021).","journal-title":"J. Intern. Med."},{"key":"81028_CR16","doi-asserted-by":"publisher","DOI":"10.1016\/j.cyto.2023.156433","volume":"173","author":"M Abdel-Salam Elgohary","year":"2024","unstructured":"Abdel-Salam Elgohary, M. et al. Even one dose of tocilizumab could hinder bad prognosis of cytokines storm in COVID-19 patients. Cytokine 173, 156433. https:\/\/doi.org\/10.1016\/j.cyto.2023.156433 (2024).","journal-title":"Cytokine"},{"key":"81028_CR17","doi-asserted-by":"publisher","first-page":"e742","DOI":"10.1093\/cid\/ciaa1445","volume":"72","author":"J Malgie","year":"2021","unstructured":"Malgie, J., Schoones, J. W. & Pijls, B. G. Decreased mortality in coronavirus disease 2019 patients treated with tocilizumab: A rapid systematic review and meta-analysis of observational studies. Clin. Infect. Dis. 72, e742\u2013e749. https:\/\/doi.org\/10.1093\/cid\/ciaa1445 (2021).","journal-title":"Clin. Infect. Dis."},{"key":"81028_CR18","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1016\/s2213-2600(21)00081-3","volume":"9","author":"AS Soin","year":"2021","unstructured":"Soin, A. S. et al. Tocilizumab plus standard care versus standard care in patients in India with moderate to severe COVID-19-associated cytokine release syndrome (COVINTOC): An open-label, multicentre, randomised, controlled, phase 3 trial. Lancet Respir. Med. 9, 511\u2013521. https:\/\/doi.org\/10.1016\/s2213-2600(21)00081-3 (2021).","journal-title":"Lancet Respir. Med."},{"key":"81028_CR19","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1056\/NEJMoa2030340","volume":"384","author":"C Salama","year":"2021","unstructured":"Salama, C. et al. Tocilizumab in patients hospitalized with Covid-19 pneumonia. N. Engl. J. Med. 384, 20\u201330. https:\/\/doi.org\/10.1056\/NEJMoa2030340 (2021).","journal-title":"N. Engl. J. Med."},{"key":"81028_CR20","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1001\/jamainternmed.2020.6615","volume":"181","author":"C Salvarani","year":"2021","unstructured":"Salvarani, C. et al. Effect of tocilizumab vs standard care on clinical worsening in patients hospitalized with COVID-19 pneumonia: A randomized clinical trial. JAMA Intern. Med. 181, 24\u201331. https:\/\/doi.org\/10.1001\/jamainternmed.2020.6615 (2021).","journal-title":"JAMA Intern. Med."},{"key":"81028_CR21","doi-asserted-by":"publisher","DOI":"10.1002\/rmv.2239","volume":"32","author":"T Klopfenstein","year":"2022","unstructured":"Klopfenstein, T., Gendrin, V., Kadiane-Oussou, N. J., Conrozier, T. & Zayet, S. Tocilizumab in COVID-19 pneumonia: Practical proposals based on a narrative review of randomised trials. Rev. Med. Virol. 32, e2239. https:\/\/doi.org\/10.1002\/rmv.2239 (2022).","journal-title":"Rev. Med. Virol."},{"key":"81028_CR22","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/j.jaci.2020.09.018","volume":"147","author":"JM Galv\u00e1n-Rom\u00e1n","year":"2021","unstructured":"Galv\u00e1n-Rom\u00e1n, J. M. et al. IL-6 serum levels predict severity and response to tocilizumab in COVID-19: An observational study. J. Allergy Clin. Immunol. 147, 72-80.e78. https:\/\/doi.org\/10.1016\/j.jaci.2020.09.018 (2021).","journal-title":"J. Allergy Clin. Immunol."},{"key":"81028_CR23","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaut.2020.102512","volume":"114","author":"AR Morrison","year":"2020","unstructured":"Morrison, A. R. et al. Clinical characteristics and predictors of survival in adults with coronavirus disease 2019 receiving tocilizumab. J. Autoimmun. 114, 102512. https:\/\/doi.org\/10.1016\/j.jaut.2020.102512 (2020).","journal-title":"J. Autoimmun."},{"key":"81028_CR24","doi-asserted-by":"publisher","first-page":"814","DOI":"10.1002\/jmv.25801","volume":"92","author":"P Luo","year":"2020","unstructured":"Luo, P. et al. Tocilizumab treatment in COVID-19: A single center experience. J. Med. Virol. 92, 814\u2013818. https:\/\/doi.org\/10.1002\/jmv.25801 (2020).","journal-title":"J. Med. Virol."},{"key":"81028_CR25","doi-asserted-by":"publisher","first-page":"10970","DOI":"10.1073\/pnas.2005615117","volume":"117","author":"X Xu","year":"2020","unstructured":"Xu, X. et al. Effective treatment of severe COVID-19 patients with tocilizumab. Proc. Natl. Acad. Sci. U. S. A. 117, 10970\u201310975. https:\/\/doi.org\/10.1073\/pnas.2005615117 (2020).","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"81028_CR26","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2024.113819","volume":"43","author":"M Wang","year":"2024","unstructured":"Wang, M. et al. Structural insights into IL-6 signaling inhibition by therapeutic antibodies. Cell Rep. 43, 113819. https:\/\/doi.org\/10.1016\/j.celrep.2024.113819 (2024).","journal-title":"Cell Rep."},{"key":"81028_CR27","doi-asserted-by":"publisher","first-page":"1397","DOI":"10.1016\/j.chest.2020.06.006","volume":"158","author":"CC Price","year":"2020","unstructured":"Price, C. C. et al. Tocilizumab treatment for cytokine release syndrome in hospitalized patients with coronavirus disease 2019: Survival and clinical outcomes. Chest 158, 1397\u20131408. https:\/\/doi.org\/10.1016\/j.chest.2020.06.006 (2020).","journal-title":"Chest"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-81028-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-81028-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-81028-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,28]],"date-time":"2024-11-28T15:06:53Z","timestamp":1732806413000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-81028-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,28]]},"references-count":27,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["81028"],"URL":"https:\/\/doi.org\/10.1038\/s41598-024-81028-3","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11,28]]},"assertion":[{"value":"25 June 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 November 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 November 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"29634"}}